Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

not met at the highest dose evaluated as monotherapy (1000 mg). - No evidence of altered cardiac activity was observed. - Majority of adverse events were mild and mainly occurred during the loading doses. Adverse events consisted of chills, itching and fatigue in over a third of patients. - There was a trend for increasing incidence of some mild adverse events with escalating OGX-427 doses. For example, 33% of patients at the 200-mg dose compared to 67% of patients at the 1000-mg dose had mild adverse events during the loading doses. - The half-life of OGX-427 in the blood remained constant, although there appeared to be an increase in maximum blood levels and a corresponding decease in blood clearance of OGX-427 as doses were escalated.

The combination of 800 mg OGX-427 with docetaxel was also well tolerated and escalation to 1000 mg OGX-427 with docetaxel will be evaluated next.

Circulating Tumor Cell and Tumor Marker Results

Circulating tumor cells (CTCs), an emerging metric to assess treatment effect, was evaluated at baseline before treatment and during treatment. Both total and Hsp27-positive CTCs were evaluated. Declines of 50% or greater in both total and Hsp27-positive CTCs were observed in over half of the patients in each cohort and in each cancer category. Declines in Hsp27 CTCs to 5 or less cells occurred in 27% of patients who had greater than 5 CTCs at baseline.

Reduction in tumor markers defined as declines of PSA levels in prostate cancer or CA-125 levels in ovarian cancer were also observed. A reduction in PSA level was observed in 7 of 20 patients (35%) with prostate cancer and a reduction in CA-125 levels was observed in 3 of 5 patients (60%) with ovarian cancer.

"CTCs are emerging as an exciting surrogate of anti-cancer activity. The frequent decreases in total
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's ... narrows down the product choices to a manageable shortlist of bench and floor ... to models that fit best with the customer’s industry and application. , ...
(Date:8/26/2015)... WARREN, N.J. , Aug. 26, 2015  Roka ... company focused on providing advanced testing solutions for the ... Thomas, CEO will present at the Sidoti & Company ... The conference will be held at the New York ... the presentation will be available through the investor relations ...
(Date:8/26/2015)... , August 26, 2015 Israel Proves Its ... wins 1 st place  Wayerz comes in 5 ... Israel by venture capital fund JVP, with Chinese ... US, China , Israel , ... .  Impressive achievement for the Israeli representatives in the ...
(Date:8/26/2015)... ... , ... The 2015 Epigenomics & Metabolomics Meeting in Boston was ... to share the first report on progress with its crowdsourcing campaign designed to ... stem cells. , With a name like “H2A.Z asymmetry,” the new biomarker would require ...
Breaking Biology Technology:METTLER TOLEDO Updates Online Scale Selection Tool 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4
... , Anne , Grabner 1 , Christoph Sachse 1 , ... , 1 Cenix BioScience GmbH, 2 ... , Sets of siRNAs focused on a specific , ... greatly increase the pace of pathway analysis and functional , ...
... Ambion now offers a complete Gene Expression Profiling Service* ... data analysis to our Full Service offering, , ... offering includes , consultation with Ambion's team ... and comprehensive data analysis. Ambion's long history of providing innovative, , ...
... Assess GAPDH siRNA delivery in less time for a fraction of the , ... Analyze from one to 96 samples simultaneously , ... toxicity , Use with Silencer ... Kit for a complete transfection optimization , solution ...
Cached Biology Technology:Assessing Gene Function with siRNA Libraries 2Assessing Gene Function with siRNA Libraries 3Assessing Gene Function with siRNA Libraries 4Assessing Gene Function with siRNA Libraries 5Assessing Gene Function with siRNA Libraries 6Assessing Gene Function with siRNA Libraries 7Ambion Offers Gene Expression Profiling Service 2Ambion Offers Gene Expression Profiling Service 3A New Way to Assess siRNA Delivery Efficiency 2A New Way to Assess siRNA Delivery Efficiency 3A New Way to Assess siRNA Delivery Efficiency 4A New Way to Assess siRNA Delivery Efficiency 5
(Date:7/31/2015)... , 31 de julio de 2015 ... (ICG-10,  www.icg-10.org ) del 22 al 25 de octubre ... La conferencia celebra su décimo aniversario este ... convertido en una de las reuniones anuales más influyentes ... es una de las conferencias científicas más dinámicas, entusiastas ...
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
(Date:7/31/2015)... Die 10. internationale Konferenz zu Genomik ... und findet vom 22. bis 25. Oktober 2015 ... Die Konferenz feiert in diesem ... ist die ICG weltweit zu einem der einflussreichsten ... eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
... - FEBS Letters, one of the leading journals for ... new enhancement to the journal article: Structured Digital Abstracts ... Letters is an extension of the regular journal article ... which contains a relationship between two biological entities, mentioning ...
... 2, 2008) Autism Speaks, the nations largest autism ... Science and one of the countrys leading autism researchers ... will examine the architecture of the autistic brain. Led ... University of California, San Diego, School of Medicine and ...
... premier forum for health care executives to explore a ... leaders. The 2008 Congress will include senior executives and ... systems, health plans, pharmaceutical and biotech companies, and government. ... Health Care Agenda, will feature key health care advisors ...
Cached Biology News:FEBS Letters Structured Digital Abstracts experiment 2Autism Speaks collaborates on grant with the Allen Institute for Brain Science and autism expert 2Autism Speaks collaborates on grant with the Allen Institute for Brain Science and autism expert 35th Annual World Health Care Congress April 21-23, Washington, D.C. 2
Recombinant Mouse Wnt-3a...
Homo sapiens jumping translocation breakpoint...
One-step, microplate or cuvet, colorimetric, detection range 0.01 g/dL to 5 g/dL. Procedure: 5 min....
Rat neural stem cell kits are intended for the in vitro growth and commitment to neuronal and glial lineage differentiation, of cultured fetal rat neural stem and progenitor cells expanded using FGF-...
Biology Products: